DK1059933T3 - Anvendelse af parathyroideahormon bestående af aminosyresekvens 1-34 af humant parathyroideahormon til reduktion af risikoen for både hvirvel- og ikke-hvirvel knoglefraktur - Google Patents

Anvendelse af parathyroideahormon bestående af aminosyresekvens 1-34 af humant parathyroideahormon til reduktion af risikoen for både hvirvel- og ikke-hvirvel knoglefraktur

Info

Publication number
DK1059933T3
DK1059933T3 DK99942350T DK99942350T DK1059933T3 DK 1059933 T3 DK1059933 T3 DK 1059933T3 DK 99942350 T DK99942350 T DK 99942350T DK 99942350 T DK99942350 T DK 99942350T DK 1059933 T3 DK1059933 T3 DK 1059933T3
Authority
DK
Denmark
Prior art keywords
parathyroid hormone
vertebral
risk
amino acid
acid sequence
Prior art date
Application number
DK99942350T
Other languages
English (en)
Inventor
Janet M Hock
Gregory A Gaich
Willard H Dere
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26792729&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1059933(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Application granted granted Critical
Publication of DK1059933T3 publication Critical patent/DK1059933T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/29—Parathyroid hormone, i.e. parathormone; Parathyroid hormone-related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Endocrinology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Orthopedics, Nursing, And Contraception (AREA)
  • Materials For Medical Uses (AREA)
  • Steroid Compounds (AREA)
DK99942350T 1998-08-19 1999-08-19 Anvendelse af parathyroideahormon bestående af aminosyresekvens 1-34 af humant parathyroideahormon til reduktion af risikoen for både hvirvel- og ikke-hvirvel knoglefraktur DK1059933T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US9715198P 1998-08-19 1998-08-19
US9974698P 1998-09-10 1998-09-10
PCT/US1999/018961 WO2000010596A1 (en) 1998-08-19 1999-08-19 Method of increasing bone toughness and stiffness and reducing fractures

Publications (1)

Publication Number Publication Date
DK1059933T3 true DK1059933T3 (da) 2003-04-07

Family

ID=26792729

Family Applications (4)

Application Number Title Priority Date Filing Date
DK10180447.4T DK2266598T3 (da) 1998-08-19 1999-08-19 Fremgangsmåde til at øge knoglehårdhed og -stivhed og at reducere brud
DK99942350T DK1059933T3 (da) 1998-08-19 1999-08-19 Anvendelse af parathyroideahormon bestående af aminosyresekvens 1-34 af humant parathyroideahormon til reduktion af risikoen for både hvirvel- og ikke-hvirvel knoglefraktur
DK15152726.4T DK2907522T3 (da) 1998-08-19 1999-08-19 Fremgangsmåde til øgning af knoglehårdhed og stivhed og reduktion af frakturer
DK06027055.0T DK1769804T3 (da) 1998-08-19 1999-08-19 hPTH(1-34) til anvendelse ved forebyggelse eller reduktion af forekomsten eller voldsomheden af vertebral og/eller ikke-vertebral fraktur hos en mand

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DK10180447.4T DK2266598T3 (da) 1998-08-19 1999-08-19 Fremgangsmåde til at øge knoglehårdhed og -stivhed og at reducere brud

Family Applications After (2)

Application Number Title Priority Date Filing Date
DK15152726.4T DK2907522T3 (da) 1998-08-19 1999-08-19 Fremgangsmåde til øgning af knoglehårdhed og stivhed og reduktion af frakturer
DK06027055.0T DK1769804T3 (da) 1998-08-19 1999-08-19 hPTH(1-34) til anvendelse ved forebyggelse eller reduktion af forekomsten eller voldsomheden af vertebral og/eller ikke-vertebral fraktur hos en mand

Country Status (32)

Country Link
US (2) US6977077B1 (da)
EP (3) EP2266598B1 (da)
JP (5) JP2002523375A (da)
KR (1) KR100454207B1 (da)
CN (1) CN1205997C (da)
AR (1) AR033639A1 (da)
AT (1) ATE231000T1 (da)
AU (1) AU746277B2 (da)
BR (1) BR9909445A (da)
CA (1) CA2325371C (da)
CO (1) CO5130020A1 (da)
CY (2) CY1113343T1 (da)
CZ (1) CZ301017B6 (da)
DE (2) DE69904918T2 (da)
DK (4) DK2266598T3 (da)
DZ (1) DZ2873A1 (da)
EA (1) EA003362B1 (da)
ES (4) ES2393200T3 (da)
HR (1) HRP20000755A2 (da)
HU (2) HU230697B1 (da)
ID (1) ID29039A (da)
IL (2) IL138829A0 (da)
MY (1) MY129227A (da)
NO (2) NO323984B1 (da)
NZ (1) NZ507056A (da)
PE (1) PE20001089A1 (da)
PL (1) PL201688B1 (da)
PT (4) PT2266598T (da)
TR (1) TR200003455T2 (da)
TW (1) TW576747B (da)
UA (1) UA72205C2 (da)
WO (1) WO2000010596A1 (da)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6770623B1 (en) * 1997-12-09 2004-08-03 Eli Lilly And Company Stabilized teriparatide solutions
AR033639A1 (es) 1998-08-19 2004-01-07 Lilly Co Eli Uso de hormonas paratiroideas para preparar medicamentos para reducir el riesgo de fracturas oseas vertebrales o no vertebrales en seres humanos con riesgo de padecer o que padecen osteoporosis
US20040033950A1 (en) 2000-09-26 2004-02-19 Hock Janet M. Method of increasing bone toughness and stiffness and reducing fractures
EP1222465A1 (en) * 1999-09-20 2002-07-17 Eli Lilly And Company Method for monitoring treatment with a parathyroid hormone
US7247609B2 (en) 2001-12-18 2007-07-24 Universitat Zurich Growth factor modified protein matrices for tissue engineering
AU2003207512B2 (en) 2002-01-10 2008-06-12 Osteotrophin Llc Treatment of bone disorders with skeletal anabolic drugs
US8088734B2 (en) 2003-01-21 2012-01-03 Unigene Laboratories Inc. Oral delivery of peptides
JP2007505883A (ja) * 2003-09-19 2007-03-15 ファイザー・プロダクツ・インク ２−アルキリデン−１９−ノル−ビタミンｄ誘導体及び副甲状腺ホルモンの組合せを含んでなる医薬組成物及び方法
US20060127320A1 (en) * 2004-05-10 2006-06-15 Nastech Pharmaceutical Company Inc. Method of delivering parathyroid hormone to a human
CA2567056A1 (en) * 2004-05-10 2005-12-08 Nastech Pharmaceutical Company Inc. Compositions and methods for enhanced mucosal delivery of parathyroid hormone
US20060052305A1 (en) * 2004-05-10 2006-03-09 Nastech Pharmaceutical Company Inc. Method of treating osteoporosis using intranasal parathyroid hormone
US20060189533A1 (en) * 2004-05-10 2006-08-24 Nastech Pharmaceutical Company Inc. Stable pharmaceutical dosage forms of teriparatide
EP1744683B1 (en) 2004-05-13 2016-03-16 Alza Corporation Apparatus and method for transdermal delivery of parathyroid hormone agents
US7648965B2 (en) 2004-05-14 2010-01-19 Unigene Laboratories Inc. Method for fostering bone formation and preservation
WO2006124062A1 (en) * 2005-05-11 2006-11-23 Unigene Laboratories, Inc. Method for fostering bone formation and preservation
US20060069021A1 (en) * 2004-08-13 2006-03-30 Nastech Pharmaceutical Company Inc. Compositions and methods for intranasal administration of inactive analogs of PTH or inactivated preparations of PTH or PTH analogs
WO2006073711A2 (en) * 2005-01-06 2006-07-13 Kuros Biosurgery Ag Use of a matrix comprising a contrast agent in soft tissues
US8575101B2 (en) 2005-01-06 2013-11-05 Kuros Biosurgery Ag Supplemented matrices for the repair of bone fractures
US20070173447A1 (en) * 2005-10-25 2007-07-26 Nastech Pharmaceutical Company Inc. Method for treating osteoporosis by intranasal delivery of teriparatide with an anti-resorptive agent
AU2006315132A1 (en) * 2005-11-10 2007-05-24 Board Of Control Of Michigan Technological University Black bear parathyroid hormone and methods of using black bear parathyroid hormone
US20080051332A1 (en) * 2005-11-18 2008-02-28 Nastech Pharmaceutical Company Inc. Method of modulating hematopoietic stem cells and treating hematologic diseases using intranasal parathyroid hormone
US20080119408A1 (en) * 2006-07-07 2008-05-22 Nastech Pharmaceutical Company Inc. Pth formulations for intranasal delivery
EP1961765A1 (en) * 2006-12-08 2008-08-27 Zealand Pharma A/S Truncated PTH peptides with a cyclic conformation
ATE543520T1 (de) 2007-04-13 2012-02-15 Kuros Biosurgery Ag Polymergewebeversiegelung
US20110137243A1 (en) * 2007-09-06 2011-06-09 Abbott Cardiovascular Systems Inc. Coating On A Balloon Device
US9457056B2 (en) * 2007-12-04 2016-10-04 Ben-Gurion University Of The Negev Research And Development Authority Peptides comprising alternating hydrophobic and anionic amino acids for treatment of osteoporosis
WO2009083544A2 (en) 2007-12-28 2009-07-09 Kuros Biosurgery Ag Pdgf fusion proteins incorporated into fibrin foams
KR20170089017A (ko) * 2009-09-09 2017-08-02 아사히 가세이 파마 가부시키가이샤 1회당 100∼200 단위의 ｐｔｈ가 주 1회 투여되는 것을 특징으로 하는, ｐｔｈ 함유 골다공증 치료/예방제
JP2013512688A (ja) 2009-12-07 2013-04-18 ミシガン テクノロジカル ユニバーシティ クロクマの副甲状腺ホルモン及びクロクマの副甲状腺ホルモンを使用する方法
US9295663B2 (en) 2010-07-14 2016-03-29 Abbott Cardiovascular Systems Inc. Drug coated balloon with in-situ formed drug containing microspheres
WO2012111852A1 (ja) * 2011-02-17 2012-08-23 帝人ファーマ株式会社 椎体骨折治療剤及びその評価方法
ES2882852T3 (es) 2011-03-16 2021-12-02 Kuros Biosurgery Ag Formulación farmacéutica para la utilización en la fusión espinal
KR20140001255A (ko) 2011-06-07 2014-01-06 아사히 가세이 파마 가부시키가이샤 고순도 ｐｔｈ 함유 동결 건조 제제 및 그의 제조 방법
US9700485B2 (en) 2013-04-24 2017-07-11 Corning Incorporated Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
AU2017214277B2 (en) 2016-02-01 2020-02-27 Eli Lilly And Company Parathyroid hormone – anti-RANKL antibody fusion compounds
WO2018144719A1 (en) * 2017-02-01 2018-08-09 The Johns Hopkins University Parathyroid hormone and regeneration of degenerative discs disease
CN116898955A (zh) * 2017-09-22 2023-10-20 旭化成制药株式会社 稳定性优异的含有特立帕肽的液态药物组合物
ES3009869T3 (en) 2018-10-29 2025-03-31 Asahi Kasei Pharma Corp An improved teriparatide dosage regimen for use in preventing or treating osteoporosis characterized by administering teriparatide or salt thereof twice a week
EP4010360A1 (en) 2019-08-09 2022-06-15 Flagship Pioneering Innovations VI, LLC Modulators of parathyroid hormone receptor (pthr1)
GB2590692A (en) * 2019-12-24 2021-07-07 Corthotec Ltd Composition for improved bone fracture healing

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4086196A (en) 1975-03-28 1978-04-25 Armour Pharmaceutical Company Parathyroid hormone
IL78342A (en) * 1985-04-04 1991-06-10 Gen Hospital Corp Pharmaceutical composition for treatment of osteoporosis in humans comprising a parathyroid hormone or a fragment thereof
DE3935738A1 (de) 1989-10-27 1991-05-08 Forssmann Wolf Georg Arzneimittel, enthaltend das humane parathormon-fragment (1-37) als aktiven wirkstoff
US5208041A (en) 1991-05-23 1993-05-04 Allelix Biopharmaceuticals Inc. Essentially pure human parathyroid hormone
CA2126299C (en) 1994-06-20 2000-12-12 Gordon E. Willick Parathyroid hormone analogues for the treatment of osteoporosis
JPH0873376A (ja) * 1994-09-07 1996-03-19 Asahi Chem Ind Co Ltd 骨粗鬆症治療薬
EP0800405A4 (en) * 1994-12-19 1998-11-11 Beth Israel Hospital CONTINUOUS LOW-DOSE ADMINISTRATION OF PARATHYROIDHORMONE OR THEIR AGONIST
US5747456A (en) 1994-12-19 1998-05-05 Beth Israel Deaconess Medical Center Continuous low-dose administration of parathyroid hormone or its agonist
CA2206657C (en) * 1994-12-22 2009-05-19 Astra Aktiebolag Therapeutic preparation for inhalation containing parathyroid hormone, pth
JPH08310965A (ja) * 1995-05-16 1996-11-26 Chugai Pharmaceut Co Ltd 骨癒合促進剤
CN1210059C (zh) 1997-09-09 2005-07-13 弗·哈夫曼-拉罗切有限公司 使用PTHrP类似物的骨折愈合
MY120063A (en) 1997-12-09 2005-08-30 Lilly Co Eli Stabilized teriparatide solutions
AR033639A1 (es) 1998-08-19 2004-01-07 Lilly Co Eli Uso de hormonas paratiroideas para preparar medicamentos para reducir el riesgo de fracturas oseas vertebrales o no vertebrales en seres humanos con riesgo de padecer o que padecen osteoporosis
US20040033950A1 (en) * 2000-09-26 2004-02-19 Hock Janet M. Method of increasing bone toughness and stiffness and reducing fractures
US6907597B1 (en) 2000-10-13 2005-06-14 Ati International Srl Method and apparatus for constructing an executable program in memory
US6967759B2 (en) 2001-12-31 2005-11-22 Texas Instruments Incorporated Pulse width modulation sequence generation
JP5796714B2 (ja) 2012-01-13 2015-10-21 株式会社リコー 定着装置及び画像形成装置
EP2949301B1 (en) 2014-05-27 2018-04-18 The Procter and Gamble Company Absorbent core with curved and straight absorbent material areas

Also Published As

Publication number Publication date
DZ2873A1 (fr) 2003-12-15
DK2907522T3 (da) 2017-10-23
KR20010072763A (ko) 2001-07-31
HUP0101594A2 (hu) 2001-11-28
CA2325371C (en) 2004-08-17
ES2621653T3 (es) 2017-07-04
DE15152726T1 (de) 2015-12-10
PE20001089A1 (es) 2000-11-04
NO323984B1 (no) 2007-07-30
NZ507056A (en) 2003-10-31
WO2000010596A1 (en) 2000-03-02
EP2266598A1 (en) 2010-12-29
KR100454207B1 (ko) 2004-10-26
CY1119552T1 (el) 2018-03-07
AU746277B2 (en) 2002-04-18
DE69904918T2 (de) 2003-11-13
JP6177718B2 (ja) 2017-08-09
ES2549551T1 (es) 2015-10-29
HUP0101594A3 (en) 2002-01-28
PT1769804E (pt) 2012-11-13
PL201688B1 (pl) 2009-04-30
US6977077B1 (en) 2005-12-20
HU230697B1 (hu) 2017-09-28
CZ301017B6 (cs) 2009-10-14
EP1059933A1 (en) 2000-12-20
NO20005947D0 (no) 2000-11-24
TR200003455T2 (tr) 2001-06-21
IL138829A0 (en) 2001-10-31
HK1212602A1 (en) 2016-06-17
DK1769804T3 (da) 2012-10-15
ES2549551T3 (es) 2017-11-27
HU1200430D0 (hu) 2001-11-28
JP2017190332A (ja) 2017-10-19
JP2011021035A (ja) 2011-02-03
PT1059933E (pt) 2003-06-30
US7163684B2 (en) 2007-01-16
DE69904918D1 (de) 2003-02-20
ES2393200T3 (es) 2012-12-19
AR033639A1 (es) 2004-01-07
AU5575099A (en) 2000-03-14
JP2014139220A (ja) 2014-07-31
EA200001015A1 (ru) 2001-02-26
EP1059933B1 (en) 2003-01-15
HK1030545A1 (en) 2001-05-11
MY129227A (en) 2007-03-30
BR9909445A (pt) 2000-12-12
CY1113343T1 (el) 2016-06-22
TW576747B (en) 2004-02-21
CN1308545A (zh) 2001-08-15
IL138829A (en) 2011-01-31
CN1205997C (zh) 2005-06-15
EA003362B1 (ru) 2003-04-24
PT2266598T (pt) 2017-05-02
PT2907522T (pt) 2017-10-23
CA2325371A1 (en) 2000-03-02
US20050197294A1 (en) 2005-09-08
JP2002523375A (ja) 2002-07-30
CO5130020A1 (es) 2002-02-27
UA72205C2 (uk) 2005-02-15
ATE231000T1 (de) 2003-02-15
NO20005947L (no) 2000-11-24
HRP20000755A2 (en) 2001-02-28
EP2907522B1 (en) 2017-08-02
ES2190244T3 (es) 2003-07-16
HK1102496A1 (en) 2007-11-23
PL343595A1 (en) 2001-08-27
EP2266598B1 (en) 2017-02-22
NO20072983L (no) 2000-11-24
ID29039A (id) 2001-07-26
EP2907522A1 (en) 2015-08-19
CZ20004134A3 (cs) 2001-08-15
JP2015028065A (ja) 2015-02-12
DK2907522T1 (da) 2015-10-19
DK2266598T3 (da) 2017-05-15

Similar Documents

Publication Publication Date Title
DK1059933T3 (da) Anvendelse af parathyroideahormon bestående af aminosyresekvens 1-34 af humant parathyroideahormon til reduktion af risikoen for både hvirvel- og ikke-hvirvel knoglefraktur
DK1021410T3 (da) Prostaglandinagonister og deres anvendelse til behandling af knogletilstande
DE59907286D1 (de) Marknagel zur Knochendistraktion
ATA131798A (de) Implantat zur gegenseitigen fixierung zweier knochenfragmente
DE50008238D1 (de) Aktiver marknagel zur distraktion von knochenteilen
AU2002362220A8 (en) Bone fasteners and method for stabilizing vertebral bone facets using the bone fasteners
DE60117664D1 (de) System zur Befestigung von Weichgewebe an Knochen
DK1223927T3 (da) Anvendelse af retigabin til behandling af neuropatiske smerter
FI981916A7 (fi) Menetelmät kudoksen muodostumisen aiheuttamiseksi käyttäen luun morfog eneettisen proteiinin ja lisäkilpirauhashormonin kaltaisen peptidin yh distelmää
ATE294539T1 (de) Knochenfixationssystem
PL339449A1 (en) Treatment of bone fractures involving the use of pthrp analogues
EP1567072A4 (en) BONE BREAKING FIXING SYSTEM OPERATING IN MULTIPLE DIRECTIONS AND ACTUATING STABILIZING PINS IN ONE DIRECTION
EP1691699A4 (en) BONE FIXING ARRANGEMENT AND FASTENING METHOD
AU2003271571A8 (en) Surgical nail and screw fixation system
DK1139891T3 (da) Anordning til udvendig fiksering af knoglebrud, især brud på ankelen
DE69930059D1 (de) Blockierungsmechanismus zur Fixierung der Wirbelsäule
EP1246651A4 (en) BIOACTIVE AND EASTOPEROTIC BONE CEMENT
IT1293934B1 (it) Chiodo endomidollare per il trattamento delle fratture dell'anca
DK0980250T3 (da) Planteekstrakter til behandling af forøget knogleresorption
AU4568901A (en) Vertebral implant for promoting arthrodesis of the spine
PL344589A1 (en) COMPOSITION COMPRISING β-HYDROXY-β-METHYLBUTYRIC ACID AND AT LEAST ONE AMINO ACID AND METHODS OF USE
DE50014411D1 (de) Medizinisches instrument zur abtragung von gewebe, knochenzement oder dergleichen im menschlichen oder tierischen körper
DE69826451D1 (de) Anästehischer knochenzement
IT1296954B1 (it) Chiodo endomidollare per uso in osteosintesi per il trattamento chirurgico delle fratture diafisometafisarie di femore e di tibia,
IL166577A0 (en) Radioactively labelled amino acid analogues their preparation and use